Dual-label time-resolved immunofluorometric of free and total prostate- specific antigen on recombinant Fab fragments

Clinical Chemistry

Volumn 46, Issue 5, 2000, Pages 658-666

  Eriksson, Susann ^a   Vehniäinen, Markus ^a   Jansén, Tove ^a   Meretoja, Ville ^a   Saviranta, Petri ^a   Pettersson, Kim ^a   Lövgren, Timo ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EUROPIUM; IMMUNOGLOBULIN F(AB) FRAGMENT; PROSTATE SPECIFIC ANTIGEN; TERBIUM;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; IMMUNOASSAY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY;

EID: 0034127730     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.5.658     Document Type: Article

References (50)

1. 1. Hayden MS, Gilliland LK, Ledbetter JA. Antibody engineering. Curr Opin Immunol 1997;9:201-12.
2. 2. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 1992;10:163-7.
3. 3. Horn U, Strittmatter W, Krebber A, Knüpfer U, Kujau M, Wenderoth R, et al. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol 1996;46:524-32.
4. 4. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12:433-55.
5. 5. Winter G, Milstein C. Man-made antibodies [Review]. Nature 1991;349:293-9.
6. 6. Saviranta P, Pajunen M, Jauria P, Karp M, Pettersson K, Mäntsälä P, Lövgren T. Engineering the steroid-specificity of an anti-17β-estradiol Fab by random mutagenesis and competitive panning. Protein Eng 1998;11:143-52.
7. 7. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999;17:568-72.
8. 8. Lindner P, Bauer K, Krebber A, Nieba L, Kremmer E, Krebber C, et al. Specific detection of His-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Biotechniques 1997;22:140-9.
9. 9. Knappik A, Plückthun A. An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. Biotechniques 1994;17:754-61.
10. 10. Lyons A, King DJ, Owens RJ, Yarranton GT, Millican A, Whittle NR, Adair JR. Site specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng 1990;3:703-8.
11. 11. Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, et al. The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods 1992;150:77-90.
12. 12. Rodwell JD, Alvarez VL, Lee C, Lopes AD, Goers JW, King HD, et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci U S A 1986;83: 2632-6.
13. 13. Kipriyanov SM, Dübel S, Breitling F, Kontermann RE, Little M. Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies. Mol Immunol 1994;31:1047-58.
14. 14. Neri D, Natali PG, Petrul H, Soldani P, Nicotra MR, Vola R, et al. Recombinant anti-human melanoma antibodies are versatile molecules. J Investig Dermatol 1996;107:164-70.
15. 15. König T, Skerra A. Use of an albumin binding domain for the selective immobilisation of recombinant capture antibody fragments on ELISA plates. J Immunol Methods 1998;218:73-83.
16. 16. Weber TH, Käpyaho KI, Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Investig 1990;50(Suppl 201):77-82.
17. 17. Kricka LJ. Human anti-animal antibody interferences in immunological assays [Review]. Clin Chem 1999;45:942-56.
18. 18. Kricka LJ, Schmerfeld-Pruss D, Senior M, Goodman DB, Kaladas P. Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem 1990;36:892-4.
19. 19. Käpyaho K, Tanner P, Weber T. Effect of complement binding on a solid-phase immunometric TSH assay. Scand J Clin Lab Investig 1989;49:211-5.
20. 20. Vanham G, Bloemmen FJ, Ceuppens JL, Stevens EA. Influence of serum complement and rheumatoid factor on detection of immune complexes by the C1q and monoclonal rheumatoid factor solid-phase assay. J Immunol Methods 1984;73:301-11.
21. 21. Börmer OP. Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies. J Immunol Methods 1989;121:85-93.
22. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
23. 23. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
24. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
25. 25. Lövgren T, Pettersson K. Time-resolved fluoroimmunoassay, advantages and limitations. In: Van Dyke K, Van Dyke R, eds. Luminescence immunoassay and molecular applications. Boca Raton, FL: CRC Press, 1990;233-53.
26. 26. Lövgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K, et al. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995;213:888-95.
27. 27. Takalo H, Mukkala VM, Mikola H, Liitti P, Hemmilä I. Synthesis of europium (III) chelates suitable for labeling of bioactive molecules. Bioconjug Chem 1994;5:278-82.
28. 28. Mukkala VM, Mikola H, Hemmilä I. The synthesis and use of activated N-benzyl derivatives of diethylenetriaminetetraacetic acids: alternative reagents for labeling of antibodies with metal ions. Anal Biochem 1989;176:319-25.
29. 29. Bayer EA, Zalis MG, Wilchek M. 3-(N-Maleimido-propionyl)biocytin: a versatile thiol-specific biotinylating reagent. Anal Biochem 1985;149:529-36.
30. 30. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
31. 31. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
32. 32. Pettersson KS, Söderholm JR. Individual differences in lutropin immunoreactivity revealed by monoclonal antibodies. Clin Chem 1991;37:333-40.
33. 33. Kerschbaumer RJ, Hirschl S, Kaufmann A, Ibl M, Koenig R, Himmler G. Single-chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzyme-linked immunosorbent assay. Anal Biochem 1997;249:219-27.
34. 34. Raag R, Whitlow M. Single-chain Fvs [Review]. FASEB J 1995;9: 73-80.
35. 35. Hemmilä I, Mukkala VM, Latva M, Kiilholma P. Di-and tetracarboxylate derivatives of pyridines, bipyridines and terpyridines as luminogenic reagents for time-resolved fluorometric determination of terbium and dysprosium. J Biochem Biophys Methods 1993; 26:283-90.
36. 36. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
37. 37. Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998;160:1734-8.
38. 38. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 1995;41:430-4.
39. 39. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 μg/L. J Urol 1997;157:913-8.
40. 40. Takalo H, Mukkala VM, Hurskainen P. Chelate clusters - new type of luminescent lanthanide labels [Short Oral Presentation]. Second International Conference of f-Elements, August 1-6, 1994, Helsinki, Finland, OG2:126.
41. 41. Diamandis EP, Morton RC, Reichstein E, Khosravi MJ. Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. Anal Chem 1989;61:48-53.
42. 42. Borchert GH, Giai M, Diamandis EP. Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts [Letter]. J Natl Cancer Inst 1997;89:587-8.
43. 43. Kato K, Umeda U Suzuki F, Hayashi D, Kosaka A. Use of antibody Fab' fragments to remove interference by rheumatoid factors with the enzyme-linked sandwich immunoassay. FEBS Lett 1979;102: 253-6.
44. 2 conjugate and polyclonal mouse IgG. Clin Chem 1992;38:1737-42.
45. 45. Kuroki M, Matsumoto Y, Arakawa F, Haruno M, Murakami M, Kuwahara M, et al. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J Immunol Methods 1995;180:81-91.
46. 46. Zisman A, Zisman E, Lindner A, Velikanov S, Siegel YI, Mozes E. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol 1995;154:1052-5.
47. 47. Christopoulus TK, Lianidou ES, Diamandis EP. Ultrasensitive time-resolved fluorescence method for α-fetoprotein. Clin Chem 1990;36:1497-502.
48. 48. Ekins RP, Chu FW. Multianalyte microspot immunoassay - microanalytical "compact disk" of the future [Review]. Clin Chem 1991;37:1955-67.
49. 49. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-20.
50. 50. Hemminki A, Hoffrén AM, Takkinen K, Vehniäinen M, Mäkinen ML, Pettersson K, et al. Introduction of lysine residues on the light chain constant domain improves the labelling properties of a recombinant Fab fragment. Protein Eng 1995;8:185-91.